Ассоц. проф. д.м.н. Seher Nazlı Kazaz

Образование и профессиональная подготовка

• 1997–2005 — Караденизский технический университет, медицинский факультет — медицинское образование

• 2007–2012 — Караденизский технический университет, медицинский факультет, кафедра внутренних болезней — докторантура / специализация по внутренним болезням

• 2013–2017 — Университет Докуз Эйлюль, медицинский факультет, отделение медицинской онкологии — субспециализация по медицинской онкологии

Членство в научных организациях

• Член Трабзонской медицинской палаты (с 2007 года)

• Член Турецкого общества медицинской онкологии (с 2014 года)

• Член Ассоциации онкологии и иммунотерапии (с 2017 года)

A. Статьи, опубликованные в международных рецензируемых журналах

• A1. Ulusoy S, Ozkan G, Sonmez M, Mungan S, Kaynar K, Cansiz M, Kazaz N. Absence of hypoalbuminemia despite nephrotic proteinuria in focal segmental glomerulosclerosis secondary to polycythemia vera. Internal Medicine (The Japanese Society of Medicine). 2010;49(22):2477-2480. DOI: 10.2169/internalmedicine.49.4087

• A2. Ulusoy S, Ozkan G, Bektaş D, Kaynar K, Cansız M, Kazaz N. Ramsay Hunt syndrome in a renal transplantation recipient: a case report. Transplantation Proceedings. 2010;42(5):1986-1988. DOI: 10.1016/j.transproceed.2010.02.078

• A3. Ozkan G, Ulusoy S, Kaynar K, Oztuna F, Cansiz M, Kazaz N. Swine H1N1 infection in a renal transplant recipient. Experimental and Clinical Transplantation. 2010;8(4):318-320. PMID: 21143099

• A4. Sonmez M, Kazaz N, Yucel B, Topbas M, Ucar F. C950T and C1181G osteoprotegerin gene polymorphisms in myeloma bone disease. Hematology. 2014;19(4):213-216. DOI: 10.1179/1607845413Y.0000000114

• A5. Salman T, Kazaz SN, Varol U, Oflazoglu U, Unek IT, Kucukzeybek Y, Alacacioglu A, Atag E, Semiz HS, Cengiz H, Oztop I, Tarhan MO. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for patients with neuroendocrine tumors: An Izmir Oncology Group study. Chemotherapy. 2016;61(6):281-286. DOI: 10.1159/000445045

• A6. Atag E, Kazaz SN, Semiz HS, Unek IT, Sarioglu S, Yavuzsen T. Epstein-Barr virus associated lymphoepithelioma-like carcinoma of the esophagogastric junction and stomach: A case report and review of the literature. Journal of Clinical and Experimental Oncology. 2016;5(6). DOI: 10.4172/2324-9110.1000171

• A7. Kurt S, Ulukus C, Kazaz SN, Astarcıoğlu I. Bilateral ovarian metastasis of a Klatskin tumor: A rare case. Turkish Journal of Obstetrics and Gynecology. 2016;13:215-217. DOI: 10.4274/tjod.40222

• A8. Kazaz SN, Oztop I. Treatment after crizotinib resistance in ALK+ non-small-cell lung cancer. International Journal of Hematology and Oncology. 2017;27(1). DOI: 10.4999/uhod.171786

• A9. Kazaz SN, Oztop I. Treatment after first-generation epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Turkish Thoracic Journal. 2017;18:66-71. DOI: 10.5152/TurkThoracJ.2017.16042

• A10. Kazaz SN, Oztop I. Immune checkpoint inhibitors in advanced-stage non-small-cell lung cancer. Turkish Thoracic Journal. 2017;18:101-107. DOI: 10.5152/TurkThoracJ.2017.17006

• A11. Buyruk AM, Kazaz SN, Oztop I, Semiz HS, Oflazoglu U, Somali I. The use of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and mean platelet volume (MPV) as inflammatory biomarkers in the prognosis of patients with early-stage colorectal adenocarcinoma. International Journal of Hematology and Oncology. 2017;27(4):220-228. DOI: 10.4999/uhod.171711

• A12. Atag E, Semiz HS, Kazaz SN, Tuna EB, Ozdogan O, Bozkurt O, Demir O, Karaoglu A. Response to cabazitaxel beyond 20 cycles in a patient with penile metastasis of prostate cancer: A case report. Urology Journal. 2017;14(1):2985-2988. DOI: 10.22037/uj.v14i1.3697

• A13. Eren H, Aydin HR, Tumkaya L, Kazaz IO, Kalkan Y, Kazaz SN, Mercantepe T, Horsanali MO, Yilmaz A. Whortleberry protects kidney against cisplatin-induced nephrotoxicity: An experimental study. Turkish Journal of Medical Sciences. 2018;40(1):466-474.

• A14. Yildirim S, Kazaz SN, Semiz HS, Yavuzsen T, Somalı I, Ellidokuz H, Oztop I. An evaluation of the information sources of cancer patients’ relatives: A prospective survey. Journal of Cancer Education. 2019;34:913-919. DOI: 10.1007/s13187-018-1384-5

• A15. Atag E, Mutlay F, Soysal P, Semiz HS, Kazaz SN, Keser M, Ellidokuz H, Karaoglu A. Prevalence of depressive symptoms in elderly cancer patients receiving chemotherapy and influencing factors. European Journal of Geriatrics and Gerontology. 2018;18(5):365-370.

• A16. Kazaz IO, Arslan A, Çolak F, Kazaz SN, Mungan S, Karagüzel E. Bladder metastasis of gastric signet-ring cell carcinoma. Urology Case Reports. 2019;22:62-62.

• A17. Kazaz IO, Ersoz S, Colak F, Teoman AS, Kazaz SN, Karaguzel E, Kutlu O. Primary renal angiosarcoma: A case report and a short review of the literature. Indian Journal of Pathology and Microbiology. 2020;63(5):44-46.

• A18. Semiz HS, Kazaz SN, Demir N, Güç ZG, Yavuzşen T, Ellidokuz H, Oztop I, Somalı I. Prognostic significance of hematological parameters in patients with early-stage malignant melanoma. UHOD – International Journal of Hematology and Oncology. 2020;30(2):103-109.

• A19. Kazaz IO, Özgür GK, Çobanoğlu Ü, Kalyoncu Nİ, Karagüzel E, Topbaş M, Eren H, Kazaz SN, Özyavuz R. Investigation of the effects of tadalafil and telmisartan in bleomycin-induced pulmonary fibrosis in rats. Journal of Surgery and Medicine. 2020;4(8):689-692.

• A20. Fidan E, Yildirim A, Kazaz N, Fidan S, Cekic AB. The relationship between albumin-bilirubin score and survival in patients operated for pancreatic cancer. Journal of Pakistan Medical Association. 2022;72(7):1340-1344. DOI: 10.47391/JPMA.2413

• A21. Kazaz SN, Yıldırım A. Evaluation of knowledge, attitudes and behaviours about COVID-19 among cancer patients. Annals of Clinical and Analytical Medicine. 2022;13(4):389-393.

• A22. Aynacı Ö, Serdar L, Rakıcı S, Kazaz S, Canyılmaz E, Bahat Z, Zengin AY. Radiotherapy in cancer treatment during the COVID-19 pandemic: One-year results from Northeast Turkey. Turkish Journal of Oncology. 2022;37(2):200-207. DOI: 10.5505/tjo.2022.3463

• A23. Dişli Ş, Fidan E, Özdover A, Kazaz N, Özdemir F. Complementary and alternative treatment use in breast cancer patients in the Eastern Black Sea region: A cross-sectional study. Indian Journal of Medical and Paediatric Oncology. 2022;43:270-277.

• A24. Fidan E, Fidan S, Merev E, Kazaz N. The relationship between albumin–bilirubin grade and survival in hepatocellular carcinoma patients treated with sorafenib. Nigerian Journal of Clinical Practice. 2022;25(2):173-177.

B. Авторские международные/национальные книги или главы в книгах

• B1. Textbook of Gastrointestinal Oncology …

• B2. Radionuclide Therapy …

• B3. Radionuclide Therapy …

• B4. Türkiye Klinikleri Special Issue – Gynecological Cancers …

• B5. Türkiye Klinikleri Special Topics – Medical Oncology: Lung Cancer …

• B6. Türkiye Klinikleri Special Topics – Radiation Oncology …

• B7. Geriatric Oncology …

• B8. Geriatric Oncology …

• B9. Türkiye Klinikleri – Ear, Nose and Throat – Special Topics …

• B10. TTOD – Breast Cancers …

• B11. Radionuclide Therapy … Springer, 2022.

• B12. Radionuclide Therapy … (2022)

C. Статьи, опубликованные в национальных рецензируемых журналах

• C1. Keser M, Kazaz SN, Karaoglu A. Medullary Thyroid Cancer …

• C2. Semiz HS, Kazaz N, Karaoglu A. Adjuvant and Neoadjuvant Systemic Treatment in Lung Cancer …

• C3. Alandag C, Kazaz SN, Cobanoglu B. Adenoid Cystic Carcinoma …

D. Доклады, представленные на международных научных конференциях и опубликованные в сборниках

• D1. Sonmez M, Kazaz N, Yucel B …

• D2. Yavuzsen T, Demir N …

• D3. Unek IT, Kazaz SN …

• D4. Semiz HS, Unek IT …

• D5. Demir N, Unek IT …

• D6. Kazaz SN, Unek IT …

• D7. Atag E, Unek IT …

• D8. Atag E, Semiz HS …

E. Доклады, представленные на национальных научных конференциях и опубликованные в сборниках

• E1. Gülsüm Özkan …

• E2. Gülsüm Özkan …

• E3. Gülsüm Özkan …

• E4. Seher Nazlı Kazaz …

• E5. Elif Atağ …

• E6. Necla Demir …

• E7. Nazlı Kazaz …

• E8. Utku Oflazoğlu …

• E9. Seher Nazlı Kazaz …

• E10. Tarık Salman …

• E11–E33. Various case reports …

• E34. Semiz H.S., Kazaz S.N. …

• E35. Elif Atağ …

• E36. Şafak Yıldırım Dişli …

• E37. Seher Nazlı Kazaz …

• E38. Atilla Yıldırım …

F. Прочее

I. Участие в конгрессах, симпозиумах и заседаниях в качестве докладчика

• FI1. Seher Nazlı Kazaz …

• FI2. Seher Nazlı Kazaz …

• FI3. Seher Nazlı Kazaz …

• FI4. Seher Nazlı Kazaz …

• FI5. Seher Nazlı Kazaz …

• FI6. Seher Nazlı Kazaz …

• FI7. Seher Nazlı Kazaz …

• FI8. Seher Nazlı Kazaz …

• FI9. Seher Nazlı Kazaz …

• FI10. Seher Nazlı Kazaz …

• FI11. Seher Nazlı Kazaz …

• FI12. Seher Nazlı Kazaz …

• FI13. Seher Nazlı Kazaz …

• FI14. Seher Nazlı Kazaz …

• FI15. Seher Nazlı Kazaz …

• FI16. Seher Nazlı Kazaz …

• FI17. Seher Nazlı Kazaz …

• FI18. Seher Nazlı Kazaz …

• FI19. Seher Nazlı Kazaz …

• FI20. Seher Nazlı Kazaz …

• FI21. Seher Nazlı Kazaz …

• FI22. Seher Nazlı Kazaz …

• FI23. Seher Nazlı Kazaz …

II. Участие в курсах

• FII1. Karadeniz Technical University Faculty of Medicine …

• FII2. Karadeniz Technical University Faculty of Medicine …

• FII3. Turkish Society of Medical Oncology …

• FII4. Turkish Society of Medical Oncology …

• FII5. Turkish Society of Medical Oncology …

• FII6. Dokuz Eylül University Faculty of Medicine …

• FII7. Immuno-Oncology Association …

• FII8. Klinikum Oldenburg Oncological Center …

• FII9. Turkish Society of Medical Oncology …

• FII10. Turkish Society of Medical Oncology …

• FII11. Karadeniz Technical University Clinical Research Center …

• FII12. 5th Course on Immuno-Oncological and Molecular Oncological Treatments in Cancer …

III. Участие в конгрессах

• FIII1. 1st National Gastrointestinal Oncology Congress …

• FIII2. 1st Symposium on Targeted Therapies in Cancer …

• FIII3. 9th European International Kidney Cancer Symposium …

• FIII4. Turkish Society of Medical Oncology – Best of ASCO …

• FIII5. İzmir Oncology Group – 1st Rare Tumors Symposium …

• FIII6. İzmir Oncology Group – 2nd Rare Tumors Symposium …

• FIII7. 21st National Cancer Congress …

• FIII8. 2nd Immuno-Oncology and Targeted Cancer Therapies Congress …

• FIII9. 2nd Geriatric Oncology Congress …

• FIII10. 7th National Lung Cancer Congress …

• FIII11. 25th Year Symposium on Multidisciplinary Approach to Cancer …

• FIII12. 5th Symposium on Advances in Oncology …

• FIII13. 15th St. Gallen International Breast Cancer Conference 2017 …

• FIII14. 3rd Geriatric Oncology Congress …

• FIII15. 23rd National Cancer Congress …

• FIII16. ESMO 2019 …

• FIII17. EMUC 2019 …

• FIII18. ASCO 2020 …

• FIII19. 4th National Immunotherapy and Oncology Congress …

• FIII20. ESMO 2020 …

• FIII21. ASCO 2020 …

• FIII22. TAKD 2021 …

• FIII23. ASCO 2021 …

• FIII24. 10th World Melanoma Congress …

• FIII25. 5th National Immunotherapy and Oncology Congress …

• FIII26. 8th TTOK Congress

• FIII27. 9th Symposium on Advances in Oncology

• FIII28. 3rd Eskişehir Oncology Days

• FIII29. 7th Black Sea Oncology Days

• FIII30. 9th TTOK Congress

• FIII31. 6th National Immunotherapy and Oncology Congress …

IV. Участие в надлежащей клинической практике и клинических исследованиях

• PERTAIN (NCT01491737) — Investigator

• PERUSE (NCT01572038) — Investigator

• HERiTAge Protocol MYL-HER-3001 (NCT02472964) — Investigator

• ASQoP (NCT01571284) — Investigator

• ExteNET (NCT00878709) — Investigator

• D-CARE (NCT01077154) — Investigator

• Javelin Lung 200 (NCT02395172) — Investigator

• MK-3475-KEYNOTE-905 (NCT03924895) — Investigator

• MK-3475-KEYNOTE-866 (NCT03924856) — Investigator

• Tislelizumab (BGB-A317) + Chemotherapy (NCT03777657) — Principal Investigator

• MK-3475-KEYNOTE-992 (NCT04241185) — Principal Investigator

• BLC 2002 NORSE (NCT03473743) — Principal Investigator

• CBYL719K12301 — Principal Investigator